One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.
Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2020 Meeting reviewing first-line ocrelizumab compared to glatiramer acetate and dimethyl fumarate for treatment of relapsing-remitting multiple sclerosis.

SAP Partner Banner

About NeurologyLive's Multiple Sclerosis Clinical Focus page:

The NeurologyLive Multiple Sclerosis Clinical Focus center offers the latest clinical news and expert insights related to this disabling disease of the central nervous system (CNS). Content found here includes video interviews with multiple sclerosis experts and key opinion leaders in neurology sharing insights on new and emerging therapies and management techniques, including insight and perspective novel treatment techniques. 

This page offers information regarding current strategies for multiple sclerosis treatment, as well as emerging therapeutic options for the disease being presented at major medical conferences and gaining traction in the scientific literature.